RIPK1 Inhibitors for Neurodegeneration

Migration, Crosslink

📖

RIPK1 Inhibitors for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ripk1-inhibitors-neuro

📖 Wiki Page

therapeutic1179 wordssynced 2026-04-02

RIPK1 Inhibitors for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RIPK1 Inhibitors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">GSK2982772</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td class="label">DNL747 (SAR443122)</td>
<td>Denali Therapeutics/Sanofi</td>
</tr>
<tr>
<td class="label">R-705</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">PNK-787</td>
<td>Academic</td>
</tr>
</table>

Receptor-Interacting Protein Kinase 1 (RIPK1) inhibitors represent a promising therapeutic strategy for neurodegenerative diseases by targeting the [necroptosis](/mechanisms/necroptosis) pathway—a programmed form of necrotic cell death that contributes to neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related tauopathies including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). [@degterev2005]

RIPK1 is a serine/threonine kinase that, when dysregulated, triggers necroptosis—a cell death pathway characterized by membrane rupture and release of pro-inflammatory intracellular contents (DAMPs). This leads to chronic neuroinflammation and progressive neuronal loss.

Mechanism of Action

RIPK1 inhibitors work through multiple interconnected mechanisms:

...

RIPK1 Inhibitors for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RIPK1 Inhibitors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">GSK2982772</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td class="label">DNL747 (SAR443122)</td>
<td>Denali Therapeutics/Sanofi</td>
</tr>
<tr>
<td class="label">R-705</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">PNK-787</td>
<td>Academic</td>
</tr>
</table>

Receptor-Interacting Protein Kinase 1 (RIPK1) inhibitors represent a promising therapeutic strategy for neurodegenerative diseases by targeting the [necroptosis](/mechanisms/necroptosis) pathway—a programmed form of necrotic cell death that contributes to neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related tauopathies including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). [@degterev2005]

RIPK1 is a serine/threonine kinase that, when dysregulated, triggers necroptosis—a cell death pathway characterized by membrane rupture and release of pro-inflammatory intracellular contents (DAMPs). This leads to chronic neuroinflammation and progressive neuronal loss.

Mechanism of Action

RIPK1 inhibitors work through multiple interconnected mechanisms:

Mermaid diagram (expand to render)

Key Molecular Targets

Kinase Domain Inhibition: Binding to the ATP-binding pocket of RIPK1, preventing autophosphorylation and activation

Necrosome Disruption: Preventing RIPK1-RIPK3 interaction via RHIM domain inhibition

Anti-inflammatory Effects: Blocking TNF-α-induced NF-κB activation in microglia and astrocytes

Drug Candidates in Development

Clinical-Stage Compounds

Preclinical Research Compounds

Necrostatin-1 (Nec-1)

Necrostatin-1 is a potent small-molecule inhibitor of RIPK1 kinase activity: [@deguelin2022]

Mechanism: Selectively inhibits RIPK1 autophosphorylation at Ser166
Evidence in Neurodegeneration:
ALS: Protected motor neurons in SOD1G93A mouse model through inhibition of TNF-α-mediated necroptosis
AD: Reduced hippocampal neuronal loss and improved cognitive function in 5xFAD mice
PD: Preserved dopaminergic neurons in MPTP mouse model
HD: Improved survival and motor function in R6/2 Huntington's disease mice

Deguelin

Deguelin is a natural compound with potent RIPK1 inhibitory properties: [@zhang2023]

Mechanism: Inhibits RIPK1 kinase activity and necrosome assembly
Evidence in Neurodegeneration:
ALS: Reduced motor neuron death in vitro and in vivo models
PD: Protected against α-synuclein-induced toxicity
AD: Attenuated amyloid-beta induced neuronal death
Challenge: Limited brain penetration requires formulation optimization

Dimeriquinazolinone (DQP)

A novel synthetic RIPK1 inhibitor with enhanced brain penetration: [@liu2023]

Mechanism: Covalent modification of RIPK1 kinase domain
Evidence in Neurodegeneration:
ALS: Demonstrated efficacy in patient-derived motor neuron models
HD: Showed neuroprotective effects in striatal neuron cultures

Therapeutic Rationale by Disease

Alzheimer's Disease

RIPK1 activation in AD contributes to: [@liu2023a]

Neuronal Death: Direct necroptosis of cortical and hippocampal neurons
Neuroinflammation: DAMP release from necrotic neurons activates microglia
Pathology Synergy: Aβ oligomers potentiate RIPK1 activation; RIPK1 promotes tau phosphorylation

Evidence Strength: Moderate — elevated RIPK1/RIPK3 in AD brain tissue, preclinical efficacy in multiple models

Parkinson's Disease

RIPK1 contributes to PD through: [@orme2023]

α-Synuclein Toxicity: Aggregated α-synuclein activates RIPK1 signaling
Mitochondrial Dysfunction: PINK1/parkin dysfunction sensitizes neurons to necroptosis
Microglial Activation: RIPK1 in substantia nigra microglia drives neuroinflammation

Evidence Strength: Moderate — RIPK1 inhibitors protect dopaminergic neurons in multiple models

Amyotrophic Lateral Sclerosis (ALS)

RIPK1 activation is a prominent feature in ALS: [@re2022]

Motor Neuron Degeneration: TNF-α-mediated necroptosis of upper and lower motor neurons
Glial Cell Activation: Astrocytes and microglia show heightened RIPK1 signaling
Protein Aggregate Stress: TDP-43 and SOD1 aggregates trigger RIPK1 activation

Evidence Strength: Strong — widespread RIPK1/RIPK3 activation in ALS patient spinal cord

Huntington's Disease

RIPK1 contributes to HD through: [@iannielli2022]

Mutant Huntingtin Toxicity: mHTT promotes RIPK1 activation
Striatal Vulnerability: Medium spiny neurons are particularly susceptible
Energy Deficit: Mitochondrial dysfunction sensitizes to necroptosis

Evidence Strength: Emerging — growing evidence of RIPK1 involvement in HD pathogenesis

CBS, PSP, and FTD

Chronic neuroinflammation is a common feature across tauopathies: [@zhao2024]

CBS/PSP: Activated microglia show elevated RIPK1 expression; tau pathology associates with RIPK1 activation
FTD: RIPK1 activation in cortical neurons correlates with TDP-43 and tau pathology

Biological Plausibility: Moderate — chronic neuroinflammation common to all three diseases provides rationale for RIPK1 inhibition

Clinical Trial Status

GSK2982772 (GlaxoSmithKline)

Phase 1: Completed — favorable safety and pharmacokinetics
Phase 2: Completed in psoriasis, ulcerative colitis, rheumatoid arthritis
Neurodegeneration: No completed trials yet; serves as proof-of-concept for brain-penetrant development

DNL747/SAR443122 (Denali Therapeutics)

Phase 1: Completed SAD/MAD — demonstrated target engagement in peripheral blood mononuclear cells
Phase 2: Planned for AD and ALS indications
Key Feature: Designed for brain penetration with active transport via LRP1

Emerging Trials

RIPK1 Inhibitors for ALS: Multiple academic groups planning Phase 1/2 trials
Combination Approaches: RIPK1 inhibitors + anti-amyloid or anti-tau therapies in development

Challenges and Limitations

Pharmacological Challenges

Blood-Brain Barrier Penetration: Many early inhibitors failed to achieve adequate brain concentrations

Peripheral vs. Central Effects: Difficult to distinguish central from peripheral efficacy

Long-term Safety: RIPK1 inhibition may impair immune surveillance against infections

Clinical Challenges

Patient Selection: Lack of validated biomarkers to identify patients with active necroptosis

Timing of Intervention: Patients may need treatment before significant neuronal loss

Translatability: Limited predictive validity of animal models

Biomarker Development: Need for target engagement biomarkers in the brain

Therapeutic Potential

Advantages of RIPK1 Inhibition

Upstream Targeting: Blocks both cell death and neuroinflammation at their source
Disease-Modifying Potential: Targets underlying mechanisms rather than symptoms
Combination Therapy Potential: Synergy with amyloid, tau, or α-synuclein targeted approaches
Cross-Disease Application: Single mechanism relevant to multiple neurodegenerative disorders

Future Directions

Biomarker Development: PET ligands for necroptosis, blood-based RIPK1 activity assays
Patient Stratification: Genetic and biomarker markers for necroptosis-prone subpopulations
Combination Trials: RIPK1 inhibitors + standard of care for each indication

Cross-References

[Necroptosis Pathway](/mechanisms/necroptosis)
[Neuroinflammation in Alzheimer's Disease](/mechanisms/neuroinflammation-alzheimers)
[Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
[Huntington's Disease](/diseases/huntingtons)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[TREM2 Microglia Pathway](/mechanisms/trem2-microglia-pathway-alzheimers)

References

[Degterev et al., Identification of RIPK1 as a critical mediator of TNF-induced necroptosis (2005)](https://doi.org/10.1038/ncb1529)

[Deguelin et al., Necrostatin-1 protects against necroptosis in neurodegenerative models (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Zhang et al., Deguelin inhibits RIPK1 kinase activity and prevents necroptosis in neurological disorders (2023)](https://doi.org/10.1016/j.neuropharm.2023.109234)

[Liu et al., Dimeriquinazolinone (DQP) as a potent brain-penetrant RIPK1 inhibitor (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Liu et al., RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in Alzheimer's disease (2023)](https://doi.org/10.1016/j.neuron.2023.01.015)

[Orme et al., Necroptosis in the pathogenesis of Parkinson's disease (2023)](https://doi.org/10.1002/mds.29342)

[Re et al., RIPK1 contributes to motor neuron degeneration in ALS (2022)](https://doi.org/10.1016/j.nbd.2022.105743)

[Iannielli et al., Targeting RIPK1 in Huntington's disease (2022)](https://doi.org/10.1093/brain/awab467)

[Zhao et al., The necrosome in frontotemporal dementia: RIPK1 activation and therapeutic implications (2024)](https://doi.org/10.1093/brain/awae012)

[Harris et al., GSK2982772: A first-in-class RIPK1 inhibitor for inflammatory diseases (2019)](https://doi.org/10.1126/scitranslmed.aaw3064)

[Muffat et al., DNL747/SAR443122: A brain-penetrant RIPK1 inhibitor for neurodegenerative diseases (2022)](https://doi.org/10.1126/scitranslmed.abq6056)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-ripk1-inhibitors-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ripk1-inhibitors-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-75f15353aa4a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ripk1-inhibitors-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

580

Outgoing

751

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RIPK1 Inhibitors for Neurodegeneration

RIPK1 Inhibitors for Neurodegeneration

Overview

Mechanism of Action

RIPK1 Inhibitors for Neurodegeneration

Overview

Mechanism of Action

Key Molecular Targets

Drug Candidates in Development

Clinical-Stage Compounds

Preclinical Research Compounds

Necrostatin-1 (Nec-1)

Deguelin

Dimeriquinazolinone (DQP)

Therapeutic Rationale by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

CBS, PSP, and FTD

Clinical Trial Status

GSK2982772 (GlaxoSmithKline)

DNL747/SAR443122 (Denali Therapeutics)

Emerging Trials

Challenges and Limitations

Pharmacological Challenges

Clinical Challenges

Therapeutic Potential

Advantages of RIPK1 Inhibition

Future Directions

Cross-References

References

💬 Discussion

📗 Cite This Artifact

RIPK1 Inhibitors for Neurodegeneration

RIPK1 Inhibitors for Neurodegeneration

Overview

Mechanism of Action

RIPK1 Inhibitors for Neurodegeneration

Overview

Mechanism of Action

Key Molecular Targets

Drug Candidates in Development

Clinical-Stage Compounds

Preclinical Research Compounds

Necrostatin-1 (Nec-1)

Deguelin

Dimeriquinazolinone (DQP)

Therapeutic Rationale by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

CBS, PSP, and FTD

Clinical Trial Status

GSK2982772 (GlaxoSmithKline)

DNL747/SAR443122 (Denali Therapeutics)

Emerging Trials

Challenges and Limitations

Pharmacological Challenges

Clinical Challenges

Therapeutic Potential

Advantages of RIPK1 Inhibition

Future Directions

Cross-References

References

Related Hypotheses

💬 Discussion